GRAVITY
31.3.2023 04:01:28 CEST | Business Wire | Press release
Gravity (NASDAQ: GRVY), a global game company, released its new 3D platformer game, 'ALTF42', as an Early Access version on Steam on March 31, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005345/en/
ALTF42, the permadeath-style 3D platformer sequel to ALTF4, is now available as an Early Access version on Steam starting from March 31 (Graphic: Gravity)
Gravity will take charge of services related to 'ALTF42', a permadeath-style 3D platformer genre game developed by PUMKIM, a Korean game developer, based on the global publishing know-how it has accumulated over the years. ALTF42 is the official follow-up to 'ATLF4' and features an even higher level of difficulty with more dangerous traps than the previous version. The previous one, ALTF4, gained a great popularity from users around the world, topping the list in STOVE review ratings and 70,000 concurrent viewers on Twitch.
As the game is named after the shortcut for forced shutdown, 'ALT+F4', it constantly stimulates the desire to forcefully close the game throughout the play. The game is cleared when the knight character breaks through stages with various traps and reaches a specific destination without losing its life. This game is attracting the attention of many global users due to its insurmountable difficulty in contrast to the simple operation method.
In the Steam Early Access version of ALTF42, although users are only allowed to play certain stages of the game, they can experience most of the core systems. In this version, only two languages, Korean and English, are supported, and game systems such as items, costumes, traps, and supported languages will be gradually supplemented through regular updates.
Yoo Joon, Business Team Leader at Gravity, said, “Gravity is showcasing ALTF42, the official follow-up to ALTF4, which has been loved by many users across the world. I highly recommend trying out the game, as users can experience most of the game’s systems in advance, even in the Early Access version that will be released this time. Starting with ALTF42, we plan to introduce console titles of various genres sequentially, as we have signed global publishing contracts for these titles. We kindly request your continued interest and support.”
More information on ALTF42 Early Access is available at the official Stream website for ALTF42 (https://store.steampowered.com/app/2187230/ALTF42/) and inquiries on game publishing can be made via e-mail (startgravity@gravity.co.kr).
About Gravity
Gravity Co., Ltd is a Korean game company established in April 2000 and a global game company listed on NASDAQ (GRVY). The number of global cumulative accounts of Ragnarok IP, Gravity's representative IP, recorded more than 120 million as of September 30, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
